Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    " March 21, 2012":" April 20, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" March 21, 2012":" April 20, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
Condition: HIV Infection
Interventions: Drug: Tenofovir, Emtricitabine, Lopinavir/r;   Drug: Tenofovir, Emtricitabine, Raltegravir
2 Terminated The Mochudi Prevention Project ART Protocol
Condition: HIV Infections
Intervention: Drug: highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine
3 Active, not recruiting Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-MAG vaccine;   Biological: IL-12 pDNA adjuvant;   Biological: VSV HIV gag vaccine;   Biological: Placebo;   Device: Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
4 Completed
Has Results
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: D/C/F/TAF;   Drug: DRV;   Drug: COBI;   Drug: FTC/TDF;   Drug: D/C/F/TAF Placebo;   Drug: DRV Placebo;   Drug: COBI Placebo;   Drug: FTC/TDF Placebo
5 Recruiting Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Condition: HIV
Intervention: Drug: Tesamorelin for injection
6 Active, not recruiting Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
Condition: HIV Infections
Interventions: Biological: GEO-D03 DNA vaccine;   Biological: MVA/HIV62B (MVA62B) vaccine;   Biological: Placebo for GEO-D03 DNA;   Biological: Placebo for MVA62B:
7 Terminated A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy
Condition: HIV-associated Myelopathy
Interventions: Drug: Intravenous Immunoglobulin;   Drug: Placebo
8 Completed Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
Condition: HIV
Intervention: Drug: Lopinavir/ritonavir 800 mg / 200mg
9 Completed
Has Results
The Rilpivirine Cerebrospinal-fluid (CSF) Study
Condition: HIV
Intervention: Drug: Rilpivirine
10 Completed Experimental Analysis of HIV Risk Assessment Reactivity in South African Clinics
Condition: HIV Prevention and Assessment Reactivity
Interventions: Behavioral: Detailed baseline interview, enhanced HIV intervention;   Behavioral: General baseline interview, enhanced HIV intervention;   Behavioral: No baseline interview, enhanced HIV intervention;   Behavioral: Detailed baseline interview, standard of care intervention;   Behavioral: General baseline interview, standard of care intervention;   Behavioral: No baseline interview, standard of care intervention
11 Unknown 
Has Results
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg twice daily;   Drug: dolutegravir placebo twice daily;   Drug: Open-label dolutegravir 50mg twice daily
12 Completed A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: DTG;   Drug: BCV;   Drug: TVR
13 Completed Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda
Conditions: HIV;   Tuberculosis
Intervention: Other: Cellular Phone Text Message Formats
14 Unknown  Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
Conditions: Human Immunodeficiency Virus (HIV);   Tuberculosis (TB);   Latent Tuberculosis Infection (LTI)
Intervention: Drug: Isoniazid
15 Completed
Has Results
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
Conditions: Hepatitis C;   HIV
Interventions: Drug: SOF;   Drug: EFV/FTC/TDF;   Drug: EFV;   Drug: ZDV/3TC;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: DRV;   Drug: RAL;   Drug: PEG;   Drug: RBV
16 Completed HIV Prevention Intervention for Young Transgender Women
Condition: Sexual Transmission of Infection
Interventions: Behavioral: HIV prevention intervention;   Behavioral: Diet and Nutrition
17 Terminated
Has Results
Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection
Condition: Cryptococcal Infection Disseminated
Interventions: Drug: Flucytosine and fluconazole;   Drug: Fluconazole
18 Recruiting Vascular Subphenotypes of Lung Disease in HIV & COPD
Condition: Pulmonary Artery Hypertension
Intervention:
19 Recruiting Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
Conditions: Anal Cancer;   Cervical Cancer;   Lung Cancer;   Lymphoma
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: medical chart review

Study has passed its completion date and status has not been verified in more than two years.